- Earnings call transcript Q3 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day ladies and gentlemen and welcome to the Arcturus Therapeutics Third Quarter 2022 Earnings Call. Today’s conference is being recorded. At this time, I would like to turn the conference over to Kyle Gutsadt, Senior Analyst, Investor & Public Relations. Please go ahead, sir.

Kyle Gutsadt

Thank you, Keith. to progress third call. welcome update XXXX and pipeline and afternoon Arcturus quarter Therapeutics financial Good Thank all you for joining us. Today’s Payne, our Sassine, led by CEO; be Andy our call and CFO. President will and Joseph Dr. session. CSO our join the COO, Pad Chivukula, and in will for Q&A

begin, forward-looking remind that, Before the Safe provisions statements during within I statements not are Private like matters Reform of XXXX. regarding the call that would Act Securities historical made to we everyone this facts of Litigation are Harbor

see not performance. performance. may risks, of known known cause unknown issued statement are achievements press performance, with involve statements section that XX-K materially Forward-looking the company’s actual the unknown today, on assumptions earlier in the risks, and guarantees and may forward-looking the from or our to statement. those cause and They uncertainties expressed risk assumptions and release disclaimer uncertainties, They that differ and filed SEC. well results, implied as as by XX-Q factors and results, actual Forms involve Please the

future And forward-looking are will over statements statements as events turn the such only of represent to specifically Joe. to views to circumstances. I the any our such update statements reflect any XXXX. or obligation May date disclaims with X, made, that, addition, Arcturus call information, now In

Joseph Payne

potential drive who have Arcturus I The recently particularly good many worked are entire transformational did CSL and job. thank established an to to will financial global mRNA with tourist’s This one top Thank look COVI-XX, distribution, which vaccines multiple of both and star as pandemic the collaboration CSL well global vaccine a completing XX% respiratory two our based waiting and up and self on express continued the collaboration, with innovative period. commercial collaboration team further well pandemic Andy will call. the from Business on Efforts. our been million call. mRNA all with development bring amplifying an the vaccine, and dollar first additional updates profound XXX some agreements of our in of front, commercialize especially briefly by advanced billion they highlights. development development, strategic details the our Scott focus the of perspective forward agreement progress profit both will transformative leader development months. is will and of team our period Lance coming exceptional Seqirus Legal expiration and manufacturing amplifying Therapeutics. and of Kevin with influenza figures recent we tirelessly want we Together, defined novel mRNA Development the on providing announced here LUNAR and vaccines. joining vaccines up the I will over every mRNA collaboration provide disease also CSL. story Arcturus as I and a progress for and made vaccine begin the deal, are the deal, vaccines company in self This manufacturing, Skull, commercialization become my and CSL delivery plans in coming infectious amplifying about designed to platform the gratitude mRNA for of manufacturer defined extraordinary our in additional our infectious is pipeline COVID-XX delivery quarterly vaccines. will Officer with with to CSL Chief technologies. combines and infrastructure expect up the funding Carta, there leads disease led self targeting They deal self Arcturus, and heart, preparedness. billion to Vaccines behind COVID-XX, you three, extraordinary market, three royalties this listening to effective the mention The in development, vaccine pathogens and development afternoon broad that receive QX has amplifying the influenza, preparedness, influenza, years. we is very influenza become milestones. deal so These and by and at to and to develop upon manufacturing a to expertise development double-digit The all. provide for in capabilities, three but the commercialization. sharing Thank will to related commercial to Rodino collaboration BARDA. Indeed, X.X team, respiratory our tourist’s meaningful you to companies our you targeting business Seqirus, This in this for vaccines in support to characterized we positioning pipeline meaningful was deal remarkable additional and

and partnership prioritizing updates and of efforts toward commercial regulatory CSL responsible future and ARCT-XXX the is guidance its place, clinical derivatives. CSL providing we are to for in our With markets. any pertaining larger

Phase XX.X the Now Advanced an Development Research valued with Acrturus second or and provided This million our BARDA Biomedical Authority agreement. award is BARDA. This with the onto agreement recent up for at transaction external to award development safety response Acrturus’s rapid The support regulatory technology with nonclinical influenza clinical studies, mRNA for along vaccine self-amplifying platform and three-years. will X through pandemic studies. over support manufacturing, preclinical,

strategy highly relationship consistent lower dose These rapid pandemic Self-amplifying award for taken Our to strategic new our of mRNA easier protection vaccines objectives deliver are with for BARDA potential rapid a We footprint in promised that and to national U.S. essential with the BARDA establishes are a contractual meaningful advantage pandemic against lyophilized validation against it the government. the doses, important influenza disease preferable government’s This U.S. preparedness safe into with qualities and further storage. provides to the and stockpiling and low technology after response and when this and provide medicines. consideration. influenza. is effective believe with pandemic are are sought have of vaccines agreement scale-up, transport vaccines specific

streamed a I that process for also allows contract. Agreement more CSL the Acrturus when to pandemic the occurs So the Collaboration acknowledge funding. accessing have lined perform pandemic next to want Acrturus government under its BARDA may to forbid, related obligations heaven

our ARCT-XXX, therapeutic for to deficiency. this deficiency moving Now Transcarbamylase Ornithine is candidate or OTC

progression Our activity, therapeutic and candidate cycle deficient liver the enzyme have All and neurological aims quality kilogram the potentially of or X.X on B living disease. OTC of this including restore expand our slow potential cohort condition. to Phase dietary to living has address this damage, with the the in with dosed co-treatment. at dosing, per improve urea individuals the requiring subjects and steroid options the single of prevent X for life without milligrams dose study completed people ascending ARCT-XXX

continue We double whose XX design randomized living patients working will adults advance participating process with and with sites countries. several beginning identified trial dosing being dozen in enroll controlled, with Phase ARCT-XXX blind, placebo single nested disease. a clinical European is dose are The The multiple to pre-screening adolescents and in this study this quarter. through ascending X multiple executed the

liver the clinical share in company announcement year, programs. new data with simultaneously ARCT-XXX therapeutic strategically will the of additional term Next

look we So to that. forward

necessary cystic studies enable progress clinic. to studies fibrosis cystic fibrosis. non-clinical the is our is therapeutic program preclinical program, on to ARCT-XXX the cystic move and to ARCT-XXX and to to moving through fibrosis inhaled ARCT-XXX necessary our continue continue ARCT-XXX messenger for our clinic. enable progress to to move to Now nonclinical our pre-clinical the to inhaled RNA the candidate

on we data week, American The critical New and if steps at RNA potential Fibrosis the data These XXXX are new preclinical for publications ARCT-XXX. the to successful. the functional included available Three some restoration. our data in protein presented you further our today. data slides North was click support presented expression Conference an tab. NACFC inhaled website Cystic for press of required and be readily well last received are of that the on and Delivery, therapeutic at release provide messenger

So to even bronchial to presence preclinical in delivery sputum the And delivery RNA messenger These delivery, demonstrated CF mucus. these technology. to attributed Acrturus the proprietary data step be. messenger that data of critical RNA where are new and first tracheal LUNAR needs of is effective successful epithelial cells it to or getting

human messenger inhaled mice, or animal the established epithelial of bronchial however the and step ARCT-XXX CF RNA collected CF mucus at primates. ferrets levels that demonstrated ferret shared comparable wild treated their rats, donors, cells well from to protein CFTR mature noteworthy. non-CF treated donors. expression in cells On is model protein effective and with this CF a animals these model. control epithelial Wherein of These were of coats delivery data have expression, lungs. cells second in-vitro multiple robust We type were to Barrett healthy successful in critical observed data including airway previously utilizing in present models new delivery these The

restoration, epithelial cells donors. obtained observed significant of critical control robust XX% treated additional to epithelial restoration, functional obtained non-CF data or treatment, in-vitro from CF increase the donors after CFTR third compared cells, the up were ARCT-XXX. for And chloride-ion human we in As step demonstrated to a Bronchial current transporter with of activity. restoration from BECs bronchial

mucus cells So and the of of bronchial in presence delivery a Barrett to summarize, tracheal epithelial CF we have in model. mRNA successful to observed

expression chloride-ion all We of alongside CFTR to also robust of protein restoration in-vitro comparable observed controls. functional current,

those to candidate, are individuals currently by unaided We the significant ARCT-XXX available with bring therapeutic Including these this ARCT-XXX, of milestones important program. All that fibrosis. for benefits cystic living treatments. believe may

anticipate continue will We updates. ARCT-XXX CTA our year the clinical trial or provide Andy end. CFO on by a Sussine, to now I of financial pass submission to to application for call

Andrew Sassine

will XX-Q issued Thank of last Arcturus X.X analysis over third you, everyone. financial receive the eligible and agreement, XXX milestones. $X agreement provides our financial the is with release more performance. of statements to over XXXX reference billion press summary financial and upfront for Joe, year details receive will we includes in good and a begin development summary I and a a year sequential over Please earlier terms milestone the signed the week. and today of afternoon, The commercial and on with quarter billion CSL of million in performance. Under

of our flu made the CSL be are programs. which applied filings expect net company receive cost, the products XX% agreement This a the pandemic and vaccines we flu, we The We and the and up three out both HSR COVID-XX some waiting other subject In and is in Act. addition, a Harsco program will and going to against been have double-digit likely all to R&D parties on to expenses under Antitrust are over milestones for to profit provided the five vaccine preparedness, spread XX/XX transaction will is cover respect years is vaccine share product, Rodino sharing for COVID-XX profit by with respiratory royalties to the forward. eligible credits, pathogens. and other CSL filing period.

transaction million product we XXX the on expect be funded pipeline, Arcturus assuming and that and sales. closes receive three-years payment, Assuming from will current the for no we based upfront any our revenues

shareholder entered agreement and our plan. pipeline tourists study In CSL our milestones Last new of that Vinbiocare terminated week ensure Vinbiocare our take view and align potential agreement. will create existing COVID mRNA our our manufacturing assume of evaluating and our combined value. cover not global supply in the Let program strategy our with to support a agreements all mutually collaborations, comprehensive into to strategically plan license and they fit the a then advance did how costs. and new agreements we with longer-term Arcturus support COVID-XX

expenses million The XXXX. of expenses in million in ended of driven to the XX, in three XXXX. certain operating operating collected revenues within results. quarter XXXX to revenues million for for total prepare primarily due operating costs. and compared a Vinbiocare data We agreement. We I three the clinical XX.X of was XX.X continue increase XXXX third months will in months the of September manufacturing reported revenues million expenses the ended was countries. Vinbiocare September by XX, we to during now our of compared summary work lower in financial reported However, decline predominantly Vietnam closely XX.X The regulatory quarter provide of X.X third of approval to to quick the the

basic of diluted approximately $X.XX XX.X shares of September loss and the XX, for share the we of diluted a end compared to or million net reported million XX.X quarter net in Finally, and XXXX, a per per basic three of $X.XX loss or XXXX. months third

two an in BARDA Supported the we agreements, million $XX earlier, next also that these provide agreement few a to strong the mentioned signed in up company will is with the very expected to funding be over three-years. years. to Joe financial over position Acrturus by next As

Hart-Scott expiration vaccine our upon the the As achieve under company now I needed and multiple therapeutic $XXX is discussed, programs. Rodino believe creating waiting to the value that call the company period CSL Antitrust Joe. milestone back Improvements the receive for will of million to We resources has expecting pass to the from Act.

Joseph Payne

Andy. Thanks,

to our for continue to opportunities our you forward progress, updates bring back vaccine the We closing will and and are about also the continued operator and we future providing look our pleased encouraged for believe of execute enormous pipeline, company, the recent opens potential our has period now We with recent very are with highlighted excited turn vaccines meaningful We are our by our This I patients, questions. and of CSL progress. highly rewarding Seqirus of therapeutics. our of pipeline mRNA with advancement and meaningful new to agreements to we agreement on to mission our been mRNA therapeutic treatments call to shareholders. while the on

Operator

you. Piper Please go take from We will our Instructions] Rahimi Sandler. Thank first question [Operator ahead. with Yasmeen

Unidentified Analyst

this on team, (Ph) [Lauren] is Yaz. for Hi

for Just questions two you. quick

The the to far the program left what in will some timing analysis first, you be CTA? the U.S. away second, Thanks. can exactly regard is filing are color then on what from the you interim? interim the And how in provide and in for CF that and included

Joseph Payne

Sure.

or So to first are question ARCT-XXX the you referring ARCT-XXX?

Unidentified Analyst

The XXX.

Joseph Payne

Okay the share therapeutic to data with simultaneously of the that new concurrently announcement that, we programs. are XXX. indicated going liver or We our strategically

And sometime in is so going be that to XXXX.

disappointed are recruitment progress we this course, the Of year. our of with

getting around concurrent have the the disclosure be liver challenges simultaneous intend And as And incurred as important some declaration programs. year. the a going is to second fully But - the interim or understand data, look strategic data communicating communication to can to we announcement be that the not that repeat is CTA. next of we soon of we forward or of However, what is is year. there question this to we the to will therapeutic or data the additional those

remaining we not track CTA many is left little that very to left. do. filing that for is We so quarter, indicated of this there year, there Now a remain weeks on this that

So anything the application just the elements? the drafting, to yes. to It add pad respect process, remaining final is with

the work of done just it. we in drafting are process is the the been So has and all That filing.

Unidentified Analyst

Perfect. Thank so much. you

Operator

We take question will next ahead. Fernandez Seamus with Guggenheim. Please our from go

Seamus Fernandez

questions the for Thanks guys.

CSL. it be to communications to the like can you So just how are the maybe COVID most sounds us program help understand for going of rolling from

hoping the the program program. written that talk you XXX then guys posted own for did amplifying - at recently, what a working understanding at mRNA is Just that what and to R&D be the self And of towards margin. of better how the to they how influence better about profit are is of a contract event in XX% sense around sharing want to you the kind R&D that on might least of their work. the process. second for guys How going expenses timelines that get I the for reimbursement given question communication just the to agreement, get into sort CSL

you to that may advance that and competing? should rights program guys Thanks. theirs your have program if or own wondering if influenza fact in program, Just be

Joseph Payne

is questions There there. I time. address sure. at few will them Sure, one a a

on any First the of for pertaining meaning, uses will respect ARCT-XXX or that and the knowhow sort any or the is the way, working clinical CSL in are future to of trigger and them programs, we any platform and correct if associated for on development that actively With technology and its with regulatory Acrturus’ all, is responsible program, question royalties. CSL financials milestones manufacturing flu providing that But it of efforts. derivatives. CSL them and supporting updates its guidance efforts to

a I two was XX/XX to question ratio. I or don’t But if did there I the questions? elaborate on about know that, XX/XX the and wanted Andy. to the can you that Now major address turn

Seamus Fernandez

Thank Yes, did. you you.

Operator

will Yigal Citi. We go with question next take Nochomovitz from our Please ahead.

Yigal Nochomovitz

a be kind if or profile and is a you of sort is vision monthly Hi, are CF the a you? daily, obviously. to here. is achieve? with are you mean, of early, are looking to have This I this I inhaled? How have profile program, know a John, target But weekly, hypothesis a it what there. not envision but a thinking is few all the you may the very you forward-looking what questions going Andy. answers for Just

Joseph Payne

Yes.

So have long half what a recognize we understand is does protein that, be what not to after we life. shortly able CFTR administration. protein will that, But express also the is very we

the being functional the that field. of may protein of still it. is effect, extend However, by that the And the determined effect durability

this will at how point. these speculative So often is treatments be

we do data. we until We weekly, but are know not detail the anticipating that collect

Yigal Nochomovitz

Okay clinical a question also then And got on it. OTC.

In reduction looking to to achieve achieve? want what to what there your are proof of see you terms threshold you that concept, on is ammonia

Joseph Payne

Its to of enzyme for Yes, normal been and in that understanding the the field XX%. publications it thankfully four from analysis of function. is that shared, have ranges sort what that have maturing. restoration of And is seen we required

if establish that viewed disease, or as be be X% preventing young males. which would is very in restoration So And to would this there way XX% to normality in general. protein in expected up especially meaningful protein is restoration for all required then death, the

Yigal Nochomovitz

know think be year. own this their program a that Okay answer they one. might they in And next press you if release but I more got with flu then, starting It it. I can the CSL - of are mentioned don’t CSL vaccine question,

So, program, does that program going vaccine work? to work be backup how that or is all on a flu might or parallel your they a

Joseph Payne

Yes.

subsequent either respect refer these combined trigger a with But of of milestones it the we a move which best our comes as it uses this knowhow, long are on advanced the be to say that CSL. out financials in and think to is technology successful, efforts or it Whatever I portion ultimately one combining it to programs going to our as to is of will we full of forward royalty. are programs or manufacturing you development, of selected program.

Yigal Nochomovitz

Okay. Thank you.

Operator

Pete question with our We Fitzgerald. ahead. will Cantor take Stavropoulos next Please go from

Pete Stavropoulos

presentation on well quick terms the the programs population you question development, know and in patient of gene the one OTC, when OTC the have I onset neonatal is It program. as and of other think heterogeneity in about as therapies. more a late so, as such the

sort how you and you treatment the achieves for the of target landscape? hope XXX Assuming evolving do into fitting product see where this profile,

Joseph Payne

is to being a candidate a advantages the flexibility messenger or ability wide Therapeutic attenuate It which would and disease higher that something for significant lower adjustable therapeutic. dosing. presentation any a and transient And variety means that RNA effect, are Arcturus be effects that there. OTC adjusted some this is There is that observed also may in it in is is dosing in nature. of transient require There of There this that the cases so provides. side dosing

We especially far to deficiency candidate. the also least so OTC is in community. therapeutic with advantage this lack potentially co-treatment steroid a a respect this considerable at And

of add? to we all anything And So Pad, elements. else bring forward those then

Padmanabh Chivukula

when is mRNA replacement other a think is disease, point we this is neonatal One solution. younger an that with after protein so ideal kids a going the

Joseph Payne

out Versus there. other the Correct. options

Pete Stavropoulos

Yes.

from usually So, my OTC of I that guess, liver part need understanding. patients neonatal transplant a

a this So liver replacing that for need transplant or as more a as bridging you do agent? view

Joseph Payne

as to and bridge be the is intent and cases that a a throughout next stage for in on will replace But help normalcy data age I absolutely the of guide and medicine. decisions. you be to mean, to full of need year to participant liver disruptive any some next for life protein just used the get as the collect the But those extend we it therapy. establish may depending or, the Both, transplant really

Pete Stavropoulos

milestones provide And Okay. color from agreement? the near-term you CSL can on any

Joseph Payne

in We billion I will that that. address let did there development across targets, Andy milestones mention five is Andy. X.X but

Andrew Sassine

Yes.

are that specific We the to what milestones. COVID-XX we be by are to have covered articulated to give because going programs not going near-term, the is

I given So have that least be significantly. certainly will of it runway I three-years. will guidance that extend think our kind at And

near-term about any perspective that terms should alleviate funding. that from So

Pete Stavropoulos

Thank you for taking very much my Alright. questions.

Operator

our question next Gena with Wang Please ahead. Barclays. go take We from will

Unidentified Analyst

Hi, this is Gena. for [Sheldon] (Ph) now

one two, on the on program, have CF We another the one agreements. BARDA

BC For the data line. from del FXXX CF the program, patients you cell show

population on the your therapy not trial because current the first, addressable in going patient, Phase one from class CTA, evaluate So mRNA by I is X what you the drugs. are to in are which the most suppose patient potent

is your the So award. And thoughts on share on and question X Phase could target in BARDA you population beyond? patient my the second

So is XX.X you mentioned million that over going be out spread to three-years. the

cadence receive both. covers an there So the those also we it and milestones benefit with at expect should we pandemic collaboration what overlap or pace what the from flu, CSL because or is

Joseph Payne

- then we capture we With question? I related or CTL well. to BARDA the anything But add address CF to There thinking to a there. Pad intended trial will dose questions therefore on questions transition question Great. And to to specific did strategic it that the first is involve And us the and the the when healthy I address the as quickly. Phase is patients, to there begin the Phase escalate is few volunteers. the I I I allows identify about will the address in question can the for - more dose respect and dose lock be X did quickly dose. parameters optimistic

Padmanabh Chivukula

Yes, exactly Joe as mentioned.

our So the I, then on volunteers a And into pick that study. we regulatory into will we Phase multiple and that feedback to feedback, looking is going we regulatory will healthy are dose of volunteers. going And course, are received. that that dose. on into be based we And healthy patients the be

Joseph Payne

reimbursement structure Yes. United that over States in And it on, is correct that with a agreements to see typical agreements is is to respect yes, XX that very you next But is question that, award with BARDA million value this three-years. government. cost spread the the

third respect of nothing is was there it out is how I think reimbursed. it. is And there a the with to ordinary So question? that

Unidentified Analyst

are CSL? collaboration, reimbursement covered you also by receive flu also this of the is CSL program No. so going indication from I the that pandemic mean, to one

Joseph Payne

in is obligations be give separate. my for clear to allows - us mentioned considered there. I under BARDA just I just a that, No, it I contract in to careful agreement notes CSL referring there me mentioned moment. that will is, messaging want CSL give the my new I’m the script, the but a BARDA Acrturus because entering perform guidance to the But collaboration that to agreement see partnership. and just its that

it separate agreement. is So a

We with have government. can ailment both accordingly. in on relationship We CSL working each operate as would recently of to R&D a said fields. approach they with the Acrturus, And advanced that of companies’ is call the the technologies using vaccine what the best

Unidentified Analyst

Got much. Thank it, very helpful. so you

Operator

you. Thank

our will next Jen We take Yale go Laidlaw ahead. Please question Company. from with and

Yale Jen

clear CSL the CSL and with question. new of COVID for or vaccine? will thanks want same similar COVID the that for version XXX afternoon Good start the be to the or I just vaccine be over will taking a

Joseph Payne

of imagine is future Well, messaging any the and communicated you sort all pertaining can be to of ARCT-XXX by the strategic derivatives to But going and above. and CSL. direction thinking

guidance to respect any me to would future their for So be inappropriate on provide with derivatives. thinking strategic

Yale Jen

how Maybe CF make one one or follow-up maybe can is which some should comp from treatment other comparisons based we current on preclinical ARCT-XXX, about here, comparing just mRNA based any Okay. think the more earlier that. data to you the

Joseph Payne

only or in that one But aspects utilizes many unique CF provide Pad Yes, LUNAR to know I so gaps any delivery some we is that therapeutic. will I and have comments. allow the technology. to the It additional fill start our

animal time the fifth primates. to of new proprietary is ferrets, of our the a set in is ferret differentiates pure so for and on manufacturing we secret trade have of suitably is healthy respect applied I with mice, showed we model, this the And this have how data the know-how it rats, are to in messenger it anything a But add data this think data other. with else applications. And CF to animals data. collective compared to inhalation and and this this then ones and Pad, have set model, We RNA, only

Padmanabh Chivukula

restored that data type the we wild we in From expression least seen the at we almost Obviously, Yes. very the have in-vitro generated levels. to look it have CFTR promising. very, model,

pretty is encouraging. data that So,

data sets seen yet. haven’t We similar with others

Yale Jen

Okay, on And development. congrats the great very helpful. is that

Joseph Payne

Thank Okay. you Yale.

Operator

We will Wells question take Zhu from Please next Securities. with ahead. Yanan go Fargo our

Yanan Zhu

my Hi thanks taking questions. for

in rather five So the the milestones heavily if COVID-XX that weight the so, could first weighted share different more on may of on that that to you or And and the in different be sometime that? making assume are programs wondering for new biology, year. the decision? novel the at also looking plan on you you in a COVID-XX and other de-risked or are any what next announcing considerations CSL across might program goes I’m features talking it decision, the targets Thanks. terms And a the whether that then is milestones? reasonable you different targets be into proportion

Joseph Payne

Thanks. questions. good two yes Sure,

than the true in will reiterate timelines. and disclosed of those hold of has haven’t information. will the development amounts targets, being most technologies. therapeutic shortest our the considering to the we we therapeutic that We value programs. of most very chest. and course, disclosing that, as remaining advanced With $X.X milestones milestones But timeline any vaccine add, specific value to to seriously those and that advanced the approval, are cards we the close understand our and and one, disclose not deliver that to So there five additional potential respect five new billion we is those of the respect I relative development is programs across to the other COVID-XX with while is the are of to each first targets not It

LUNAR and technology applicability the is of delivering exceptional molecules administrations at technology the that this biodegradable through that systemic administrations. realize is large to technology and inhaled come have and We and the RNA non-accumulating

our guidance, we differentiation specific the are do that. going competitors appreciate technology LUNAR technology. other it is to to to definitely There space. But So is you as with with early respect too this leverage can delivery in

be So there. provide we we will more when hints strategic

Yanan Zhu

you what you with immune CF have and studied, terms terms question Thank antibodies you. animal of add dosing may Thank sort. it. multiple reactions after for doses for models any that therein If color. antidrug multiple the program, the experience all of I a of potential is Got in things the or how the

Joseph Payne

Yes. that in received discuss I actively our with X is Pad franchise. start injected the will studies, to Phase study the was been general we X the have that that remaining animal and I our turn beings, Phase XX-hours. Well, I no after plasma time Phase there preclinical some will in But XB, collective X lipids investigated and evaluations therapeutic that we want reiterate most Phase decomposition people to and the of lipid -- has the in human looked advanced LUNAR at now to over more XX in ARCT-XXX. observed and in the then we And

So was Pad. respect other in turn or humans. to With the I positively safety immunogenic to parameters - very viewed will the over that time

Pad Chivukula

Yes.

talked this the have about past. in We

You data in might we primates, we for delivered data months that weekly recall - loss the of that the data for non-human activity OTC see Essentially, any nine-month our safety of didn’t gave we and nine-month shared dosing program. tox in the nine protein.

showed it the for pretty pre-clinically Showing a quite encouraging at So that LUNAR least was was promise. us.

Yanan Zhu

for color. Got it. Thank you the

Joseph Payne

Thanks.

Operator

for I no queue. the an would turn are or closing At questions this to there conference presenters time, your the back further to like additional remarks. in

Joseph Payne

remarks. closing No

right back away. out for Thanks participating everyone. any team Just will to the if to and questions, Goodnight. please and there we call, is remaining you to thanks on the reach get

Operator

appreciate this participation. conference. and We concludes your Ladies gentlemen, today’s

now may disconnect. You

Arcturus Therapeutics (ARCT) 10 Nov 222022 Q3 Earnings call transcript